Currently, BAFF-based CAR-T cell therapy is one of the most promising BAFF-based therapeutic modalities in clinical cancer research (Wong et al., 2022), but there have been no reports on BAFF-based antibody therapies. Here, TNFSF13B is linked to cancer.